Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.
SinoMab BioScience has announced that non-executive directors Dr. Haigang Chen and Mr. Xun Dong will resign from the board, effective 31 March 2026 and 1 April 2026 respectively, citing the need to focus on personal affairs and other work and business commitments. Both departing directors stated they have no disagreement with the board, and the company emphasized its appreciation for their contributions, signaling an orderly transition in corporate governance with the remaining executive, non-executive and independent non-executive directors continuing to oversee the group’s affairs.
The board composition following these resignations will center on Executive Director, Chairman and CEO Dr. Shui On Leung, alongside non-executive directors Ms. Xiaosu Wang and Dr. Jianmin Zhang, and a slate of independent non-executive directors including George William Hunter Cautherley and others. This refreshed board lineup suggests continuity in oversight while the company navigates its strategic and operational agenda, with no immediate indication of dispute or disruption arising from the director changes.
The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company listed on the Stock Exchange of Hong Kong, focused on developing and commercializing innovative biologic therapies. The group operates through a board structure that includes executive, non-executive and independent non-executive directors overseeing its strategic and governance responsibilities.
Average Trading Volume: 5,142,840
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.42B
Find detailed analytics on 3681 stock on TipRanks’ Stock Analysis page.